Multiple Endocrine Neoplasia

Surgical Oncology Clinics of North America

Volumn 17, Issue 2, 2008, Pages 439-459

  White, Matthew L ^a,b   Doherty, Gerard M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ST JOSEPH MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; LABETUZUMAB; SORAFENIB; SUNITINIB; TANESPIMYCIN; VANDETANIB;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER MORTALITY; CLINICAL TRIAL; DNA SCREENING; GENETIC SCREENING; HUMAN; METASTASIS; MOLECULAR BIOLOGY; MORBIDITY; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; PATHOGENESIS; RECURRENT CANCER; REVIEW; SIPPLE SYNDROME; THYROIDECTOMY;

ANTINEOPLASTIC AGENTS; DNA, NEOPLASM; GENETIC SCREENING; HUMANS; MOLECULAR BIOLOGY; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; POPULATION SURVEILLANCE;

EID: 41049097334     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.12.002     Document Type: Review

References (138)

1. Steiner A.L., Goodman A.D., and Powers S.R. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore) 47 5 (1968) 371-409
2. Marx S.J., and Simonds W.F. Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr Rev 26 5 (2005) 615-661
3. Gagel R.F., and Marx S.J. Multiple endocrine neoplasia. In: Larsen P.R., Kronenberg H.M., Melmed S., et al. (Eds). Williams textbook of endocrinology. 10th edition (2003), Saunders, Philadelphia 1717-1762
4. Kouvaraki M.A., Shapiro S.E., Perrier N.D., et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15 6 (2005) 531-544
5. Agarwal S.K., Lee Burns A., Sukhodolets K.E., et al. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci 1014 (2004) 189-198
6. Marx S.J. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5 5 (2005) 367-375
7. Carney J.A. Familial multiple endocrine neoplasia: the first 100 years. Am J Surg Pathol 29 2 (2005) 254-274
8. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med 16 3 (1954) 363-371
9. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 12 (2001) 5658-5671
10. Doherty G.M. Multiple endocrine neoplasia type 1. J Surg Oncol 89 3 (2005) 143-150
11. Doherty G.M. Parathyroid glands. In: Mulholland M.W., Lillemoe K.D., Doherty G.M., et al. (Eds). Greenfield's surgery: scientific principles and practice. 4th edition (2006), Lippincott Williams & Wilkins, Philadelphia 1310-1334
12. Wilkinson S., Teh B.T., Davey K.R., et al. Cause of death in multiple endocrine neoplasia type 1. Arch Surg 128 6 (1993) 683-690
13. Doherty G.M., Olson J.A., Frisella M.M., et al. Lethality of multiple endocrine neoplasia type I. World J Surg 22 6 (1998) 581-586 [discussion: 586-7]
14. Dean P.G., van Heerden J.A., Farley D.R., et al. Are patients with multiple endocrine neoplasia type I prone to premature death?. World J Surg 24 11 (2000) 1437-1441
15. Larsson C., Skogseid B., Oberg K., et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332 6159 (1988) 85-87
16. Chandrasekharappa S.C., Guru S.C., Manickam P., et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 5311 (1997) 404-407
17. Lemmens I., Van de Ven W.J., Kas K., et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 6 7 (1997) 1177-1183
18. Stratakis C.A., and Marx S.J. Multiple endocrine neoplasias in the era of translational medicine. Horm Metab Res 37 6 (2005) 343-346
19. Thompson G.B., and Young Jr. W.F. Multiple endocrine neoplasia type 1. In: Clark O.H., Duh Q.-Y., and Kebebew E. (Eds). Textbook of endocrine surgery. 2nd edition (2005), Saunders, Philadelphia 673-690
20. Knudson Jr. A.G. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68 4 (1971) 820-823
21. Agarwal S.K., Kennedy P.A., Scacheri P.C., et al. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res 37 6 (2005) 369-374
22. Guru S.C., Goldsmith P.K., Burns A.L., et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci U S A 95 4 (1998) 1630-1634
23. La P., Silva A.C., Hou Z., et al. Direct binding of DNA by tumor suppressor menin. J Biol Chem 279 47 (2004) 49045-49054
24. Agarwal S.K., Guru S.C., Heppner C., et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96 1 (1999) 143-152
25. Gobl A.E., Berg M., Lopez-Egido J.R., et al. Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism. Biochim Biophys Acta 1447 1 (1999) 51-56
26. Kim H., Lee J.E., Cho E.J., et al. Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res 63 19 (2003) 6135-6139
27. Kim H., Lee J.E., Kim B.Y., et al. Menin represses JunD transcriptional activity in protein kinase C theta-mediated Nur77 expression. Exp Mol Med 37 5 (2005) 466-475
28. Agarwal S.K., Novotny E.A., Crabtree J.S., et al. Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci U S A 100 19 (2003) 10770-10775
29. Knapp J.I., Heppner C., Hickman A.B., et al. Identification and characterization of JunD missense mutants that lack menin binding. Oncogene 19 41 (2000) 4706-4712
30. Sayo Y., Murao K., Imachi H., et al. The multiple endocrine neoplasia type 1 gene product, menin, inhibits insulin production in rat insulinoma cells. Endocrinology 143 6 (2002) 2437-2440
31. Schnepp R.W., Mao H., Sykes S.M., et al. Menin induces apoptosis in murine embryonic fibroblasts. J Biol Chem 279 11 (2004) 10685-10691
32. Lindsten T., Ross A.J., King A., et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 6 6 (2000) 1389-1399
33. Wei M.C., Zong W.X., Cheng E.H., et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292 5517 (2001) 727-730
34. Varfolomeev E.E., Schuchmann M., Luria V., et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9 2 (1998) 267-276
35. Schnepp R.W., Chen Y.X., Wang H., et al. Mutation of tumor suppressor gene Men1 acutely enhances proliferation of pancreatic islet cells. Cancer Res 66 11 (2006) 5707-5715
36. Hussein N., Casse H., Fontaniere S., et al. Reconstituted expression of menin in Men1-deficient mouse Leydig tumour cells induces cell cycle arrest and apoptosis. Eur J Cancer 43 2 (2007) 402-414
37. Gustavson K.H., Jansson R., and Oberg K. Chromosomal breakage in multiple endocrine adenomatosis (types I and II). Clin Genet 23 2 (1983) 143-149
38. Scappaticci S., Maraschio P., del Ciotto N., et al. Chromosome abnormalities in lymphocytes and fibroblasts of subjects with multiple endocrine neoplasia type 1. Cancer Genet Cytogenet 52 1 (1991) 85-92
39. Tomassetti P., Cometa G., Del Vecchio E., et al. Chromosomal instability in multiple endocrine neoplasia type 1. Cytogenetic evaluation with DEB test. Cancer Genet Cytogenet 79 2 (1995) 123-126
40. Itakura Y., Sakurai A., Katai M., et al. Enhanced sensitivity to alkylating agent in lymphocytes from patients with multiple endocrine neoplasia type 1. Biomed Pharmacother 54 Suppl 1 (2000) 187s-190s
41. Farnebo F., Kytola S., Teh B.T., et al. Alternative genetic pathways in parathyroid tumorigenesis. J Clin Endocrinol Metab 84 10 (1999) 3775-3780
42. Jin S., Mao H., Schnepp R.W., et al. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 63 14 (2003) 4204-4210
43. Sukhodolets K.E., Hickman A.B., Agarwal S.K., et al. The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. Mol Cell Biol 23 2 (2003) 493-509
44. Busygina V., Kottemann M.C., Scott K.L., et al. Multiple endocrine neoplasia type 1 interacts with forkhead transcription factor CHES1 in DNA damage response. Cancer Res 66 17 (2006) 8397-8403
45. Papaconstantinou M., Wu Y., Pretorius H.N., et al. Menin is a regulator of the stress response in Drosophila melanogaster. Mol Cell Biol 25 22 (2005) 9960-9972
46. Busygina V., Suphapeetiporn K., Marek L.R., et al. Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. Hum Mol Genet 13 20 (2004) 2399-2408
47. Kouvaraki M.A., Lee J.E., Shapiro S.E., et al. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg 137 6 (2002) 641-647
48. Bassett J.H., Forbes S.A., Pannett A.A., et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 62 2 (1998) 232-244
49. Kong C., Ellard S., Johnston C., et al. Multiple endocrine neoplasia type 1Burin from Mauritius: a novel MEN1 mutation. J Endocrinol Invest 24 10 (2001) 806-810
50. Olufemi S.E., Green J.S., Manickam P., et al. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Hum Mutat 11 4 (1998) 264-269
51. Petty E.M., Green J.S., Marx S.J., et al. Mapping the gene for hereditary hyperparathyroidism and prolactinoma (MEN1Burin) to chromosome 11q: evidence for a founder effect in patients from Newfoundland. Am J Hum Genet 54 6 (1994) 1060-1066
52. Teh B.T., McArdle J., Chan S.P., et al. Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1. Medicine (Baltimore) 76 1 (1997) 21-29
53. Teh B.T., Zedenius J., Kytola S., et al. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg 228 1 (1998) 99-105
54. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21 12 (2003) 2397-2406
55. Gummerman D. Final CLIA regulations released. Med Staff Couns 6 4 (1992) 51-54
56. Holtzman N.A., and Watson M.S. Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing. J Child Fam Nurs 2 5 (1999) 388-390
57. GeneTests-GeneClinics home page. Available at: http://www.geneclinics.org. Accessed June 11, 2007.
58. Balogh K., Patocs A., Majnik J., et al. Genetic screening methods for the detection of mutations responsible for multiple endocrine neoplasia type 1. Mol Genet Metab 83 1-2 (2004) 74-81
59. Shapiro S.E., Cote G.C., Lee J.E., et al. The role of genetics in the surgical management of familial endocrinopathy syndromes. J Am Coll Surg 197 5 (2003) 818-831
60. Skogseid B., Eriksson B., Lundqvist G., et al. Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 73 2 (1991) 281-287
61. Skogseid B., Rastad J., and Oberg K. Multiple endocrine neoplasia type 1. Clinical features and screening. Endocrinol Metab Clin North Am 23 1 (1994) 1-18
62. Lowney J.K., Frisella M.M., Lairmore T.C., et al. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery 124 6 (1998) 1043-1048 [discussion: 1048-9]
63. Lairmore T.C., Piersall L.D., DeBenedetti M.K., et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann Surg 239 5 (2004) 637-645 [discussion: 645-7]
64. Akerstrom G., Hessman O., and Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbecks Arch Surg 386 8 (2002) 558-569
65. Thompson N.W. Surgical treatment of the endocrine pancreas and Zollinger-Ellison syndrome in the MEN 1 syndrome. Henry Ford Hosp Med J 40 3-4 (1992) 195-198
66. Lairmore T.C., Chen V.Y., DeBenedetti M.K., et al. Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 231 6 (2000) 909-918
67. Skogseid B., Oberg K., Eriksson B., et al. Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type I. World J Surg 20 7 (1996) 872-876 [discussion: 877]
68. Hellman P., Skogseid B., Oberg K., et al. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery 124 6 (1998) 993-999
69. Rizzoli R., Green III J., and Marx S.J. Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium levels after parathyroidectomy. Am J Med 78 3 (1985) 467-474
70. Sipple J.H. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 31 1 (1961) 163-166
71. Schimke R.N. Genetic aspects of multiple endocrine neoplasia. Annu Rev Med 35 (1984) 25-31
72. Farndon J.R., Leight G.S., Dilley W.G., et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 73 4 (1986) 278-281
73. Lakhani V.T., You Y.N., and Wells S.A. The multiple endocrine neoplasia syndromes. Annu Rev Med 58 (2007) 253-265
74. Donovan D.T., Levy M.L., Furst E.J., et al. Familial cutaneous lichen amyloidosis in association with multiple endocrine neoplasia type 2A: a new variant. Henry Ford Hosp Med J 37 3-4 (1989) 147-150
75. Verdy M., Weber A.M., Roy C.C., et al. Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. J Pediatr Gastroenterol Nutr 1 4 (1982) 603-607
76. Miller C.A., and Ellison E.C. Multiple endocrine neoplasia type 2B. In: Clark O.H., Duh Q.-Y., and Kebebew E. (Eds). Textbook of endocrine surgery. 2nd edition (2005), Saunders, Philadelphia 757-763
77. Carney J.A., Go V.L., Sizemore G.W., et al. Alimentary-tract ganglioneuromatosis. A major component of the syndrome of multiple endocrine neoplasia, type 2b. N Engl J Med 295 23 (1976) 1287-1291
78. Wiesner GL, Snow-Bailey K. Multiple endocrine neoplasia type 2. In: Pagon RA, editor. GeneReviews at GeneTests-GeneClinics. Available at: http://www.geneclinics.org. Accessed June 11, 2007.
79. Ponder B.A. Multiple endocrine neoplasia type 2. In: Scriver C.R., Beaudet A.L., Sly W.S., et al. (Eds). The metabolic and molecular bases of inherited disease. 8th edition (2001), McGraw-Hill, New York 931-942
80. Machens A., Niccoli-Sire P., Hoegel J., et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349 16 (2003) 1517-1525
81. Hoff A.O., Cote G.J., and Gagel R.F. Multiple endocrine neoplasias. Annu Rev Physiol 62 (2000) 377-411
82. Takahashi M., Ritz J., and Cooper G.M. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42 2 (1985) 581-588
83. Mathew C.G., Chin K.S., Easton D.F., et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328 6130 (1987) 527-528
84. Simpson N.E., Kidd K.K., Goodfellow P.J., et al. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 328 6130 (1987) 528-530
85. Takahashi M., Buma Y., Iwamoto T., et al. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3 5 (1988) 571-578
86. Ishizaka Y., Itoh F., Tahira T., et al. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene 4 12 (1989) 1519-1521
87. Donghi R., Sozzi G., Pierotti M.A., et al. The oncogene associated with human papillary thyroid carcinoma (PTC) is assigned to chromosome 10 q11-q12 in the same region as multiple endocrine neoplasia type 2A (MEN2A). Oncogene 4 4 (1989) 521-523
88. Carlson K.M., Dou S., Chi D., et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 91 4 (1994) 1579-1583
89. Donis-Keller H., Dou S., Chi D., et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2 7 (1993) 851-856
90. Eng C., Smith D.P., Mulligan L.M., et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3 2 (1994) 237-241
91. Hofstra R.M., Landsvater R.M., Ceccherini I., et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367 6461 (1994) 375-376
92. Mulligan L.M., Kwok J.B., Healey C.S., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 6428 (1993) 458-460
93. Gardner E., Papi L., Easton D.F., et al. Genetic linkage studies map the multiple endocrine neoplasia type 2 loci to a small interval on chromosome 10q11.2. Hum Mol Genet 2 3 (1993) 241-246
94. Gschwind A., Fischer O.M., and Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4 5 (2004) 361-370
95. Santoro M., Melillo R.M., Carlomagno F., et al. Minireview: RET: normal and abnormal functions. Endocrinology 145 12 (2004) 5448-5451
96. Baloh R.H., Tansey M.G., Lampe P.A., et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 21 6 (1998) 1291-1302
97. Kotzbauer P.T., Lampe P.A., Heuckeroth R.O., et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384 6608 (1996) 467-470
98. Milbrandt J., de Sauvage F.J., Fahrner T.J., et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 20 2 (1998) 245-253
99. Treanor J.J., Goodman L., de Sauvage F., et al. Characterization of a multicomponent receptor for GDNF. Nature 382 6586 (1996) 80-83
100. Airaksinen M.S., and Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3 5 (2002) 383-394
101. Ichihara M., Murakumo Y., and Takahashi M. RET and neuroendocrine tumors. Cancer Lett 204 2 (2004) 197-211
102. Asai N., Iwashita T., Matsuyama M., et al. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15 3 (1995) 1613-1619
103. Eng C., Clayton D., Schuffenecker I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276 19 (1996) 1575-1579
104. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 17 1 (1999) 380-393
105. Menko F.H., van der Luijt R.B., de Valk I.A., et al. Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. J Clin Endocrinol Metab 87 1 (2002) 393-397
106. Miyauchi A., Futami H., Hai N., et al. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 90 1 (1999) 1-5
107. Fialkowski E.A., and Moley J.F. Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol 94 8 (2006) 737-747
108. Hubner R.A., and Houlston R.S. Molecular advances in medullary thyroid cancer diagnostics. Clin Chim Acta 370 1-2 (2006) 2-8
109. Niccoli-Sire P., Murat A., Rohmer V., et al. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab 86 8 (2001) 3746-3753
110. Margraf R.L., Mao R., Highsmith W.E., et al. RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis. J Mol Diagn 9 2 (2007) 184-196
111. Bravo E.L., and Gifford Jr. R.W. Current concepts. Pheochromocytoma: diagnosis, localization and management. N Engl J Med 311 20 (1984) 1298-1303
112. Neumann H.P., Bausch B., McWhinney S.R., et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346 19 (2002) 1459-1466
113. Elder E.E., Elder G., and Larsson C. Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. J Surg Oncol 89 3 (2005) 193-201
114. Wohllk N., Cote G.J., Bugalho M.M., et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81 10 (1996) 3740-3745
115. Dralle H., Gimm O., Simon D., et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22 7 (1998) 744-750 [discussion: 750-41]
116. Lenders J.W., Pacak K., Walther M.M., et al. Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA 287 11 (2002) 1427-1434
117. Quayle F.J., and Moley J.F. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol 89 3 (2005) 122-129
118. Yip L., Cote G.J., Shapiro S.E., et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138 4 (2003) 409-416 [discussion: 416]
119. Jindrichova S., Kodet R., Krskova L., et al. The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma. J Mol Med 81 12 (2003) 819-823
120. Kalinin V.N., Amosenko F.A., Shabanov M.A., et al. Three novel mutations in the RET proto-oncogene. J Mol Med 79 10 (2001) 609-612
121. Kitamura Y., Scavarda N., Wells Jr. S.A., et al. Two maternally derived missense mutations in the tyrosine kinase domain of the RET protooncogene in a patient with de novo MEN 2B. Hum Mol Genet 4 10 (1995) 1987-1988
122. Brierley J., Tsang R., Simpson W.J., et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6 4 (1996) 305-310
123. Wu L.T., Averbuch S.D., Ball D.W., et al. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73 2 (1994) 432-436
124. Gosnell J.E., Sywak M.S., Sidhu S.B., et al. New era: prophylactic surgery for patients with multiple endocrine neoplasia-2a. ANZ J Surg 76 7 (2006) 586-590
125. Dralle H. Lymph node dissection and medullary thyroid carcinoma. Br J Surg 89 9 (2002) 1073-1075
126. White M.L., Gauger P.G., and Doherty G.M. Central lymph node dissection in differentiated thyroid cancer. World J Surg 31 5 (2007) 895-904
127. Moley J.F., and DeBenedetti M.K. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229 6 (1999) 880-887 [discussion: 887-8]
128. Moley J.F., Dilley W.G., and DeBenedetti M.K. Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 225 6 (1997) 734-740 [discussion: 740-3]
129. Gumbs A.A., and Gagner M. Laparoscopic adrenalectomy. Best Pract Res Clin Endocrinol Metab 20 3 (2006) 483-499
130. Yip L., Lee J.E., Shapiro S.E., et al. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198 4 (2004) 525-534 [discussion: 534-5]
131. Raue F., Kraimps J.L., Dralle H., et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 238 4 (1995) 369-373
132. Kraimps J.L., Denizot A., Carnaille B., et al. Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d'Etude des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg 20 7 (1996) 808-812 [discussion: 812-3]
133. Cohen M.S., Hussain H.B., and Moley J.F. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132 6 (2002) 960-966 [discussion: 966-7]
134. de Groot J.W., Zonnenberg B.A., Plukker J.T., et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78 4 (2005) 433-438
135. Carlomagno F., Anaganti S., Guida T., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98 5 (2006) 326-334
136. Kim D.W., Jo Y.S., Jung H.S., et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91 10 (2006) 4070-4076
137. Sharkey R.M., Hajjar G., Yeldell D., et al. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46 4 (2005) 620-633
138. Marsee D.K., Venkateswaran A., Tao H., et al. Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. J Biol Chem 279 42 (2004) 43990-43997